FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy

Brainstorm Cell Therapeutics

25/09/2023 13:13

Sept 25 (Reuters) - The U.S. Food and Drug
Administration's staff reviewers raised concerns on Monday over
the safety and efficacy of BrainStorm Cell Therapeutics'
amyotrophic lateral sclerosis (ALS) therapy.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Mariam.ESunny@thomsonreuters.com;))